Ghorbani, Atefeh
Chatanaka, Miyo K.
Avery, Lisa M.
Wang, Mingyue
Brown, Jermaine
Cohen, Rachel
Gorham, Taron
Misaghian, Salvia
Padmanabhan, Nikhil
Romero, Daniel
Stengelin, Martin
Mathew, Anu
Sigal, George
Wohlstadter, Jacob
Horbinski, Craig
McCortney, Katy
Xu, Wei
Zadeh, Gelareh
Mansouri, Alireza
Yousef, George M.
Diamandis, Eleftherios P.
Prassas, Ioannis
Funding for this research was provided by:
SPORE for Translational Approaches to Brain Cancer (P50CA221747)
Canadian Institutes for Health Research, The Canadian Brain Foundation, Canadian Cancer Society Research Institute (CCS707057)
Article History
Received: 1 February 2024
Accepted: 29 May 2024
First Online: 15 June 2024
Declarations
:
: This study was approved under the Research Ethics Board (REB) of Sinai Health System in Toronto, Canada, under the REB number 21–0114-E.
: Not applicable.
: MW, JB, RC, TG, SM, NP, DR, MS, AM and GS are employees and JW is an officer of Meso Scale Diagnostics, LLC. Otherwise, the authors did not identify any potential, perceived or real conflicts of interest to disclose.